Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis

Journal of the American Society of Nephrology

Volumn 9, Issue 7, 1998, Pages 1202-1212

  Tomasoni, Susanna ^a   Noris, Marina ^a,b   Zappella, Sergio ^a   Gotti, Eliana ^a   Casiraghi, Federica ^a   Bonazzola, Samantha ^a   Benigni, Ariela ^a   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CD68 ANTIGEN; CYCLOOXYGENASE 2; PEROXIDASE; PROSTAGLANDIN; THROMBOXANE A2;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0031798859     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Hahn BH: Systemic lupus erythematosus. In: Principles of Internal Medicine, edited by Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, New York, McGraw Hill, 1987, pp 1418-1423
2. Tanaka Y: Production of B cell-stimulating factors by B cells in patients with lupus erythematosus. J Immunol 141: 3043-3049, 1988
3. Glassock RJ, Brenner BM: Glomerulopathies associated with multisystem diseases. In: Principles of Internal Medicine, edited by Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin J, Fauci AS, New York, McGraw Hill, 1987, pp 1183-1189
4. Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow JE: Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int 25: 689-695, 1984
5. Alexopoulus E, Seron D, Hartley RB, Cameron S: Lupus nephritis: Correlation of interstitial cells with glomerular function. Kidney Int 37: 100-109, 1990
6. D'Agati VD, Appel GB, Estes D, Knowles II, Pirani CL: Monoclonal antibody identification of infiltrating mononuclear leukocytes in lupus nephritis. Kidney Int 30: 573-581, 1986
7. Noris M, Bernasconi S, Casiraghi F, Sozzani S, Gotti E, Remuzzi G, Mantovani A: Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 73: 804-809, 1995
8. Zoja C, Liu XH, Donadelli R, Abbate M, Testa D, Corna D, Taraboletti G, Vecchi A, Dong QG, Rollins BJ, Bertani T, Remuzzi G: Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol 8: 720-729, 1997
9. Remuzzi G, Fitzgerald GA, Patrono C: Thromboxane synthesis and action within the kidney. Kidney Int 41: 1483-1493, 1992
10. Stahl RAK, Thaiss F, Kahf S, Schoeppe W, Helmchen UM: Immune-mediated mesangial cell injury: Biosynthesis and function of prostanoids. Kidney Int 38: 273-281, 1990
11. Kelley VE, Sneve S, Musinski S: Increased renal thromboxane production in murine lupus nephritis. J Clin Invest 77: 252-259, 1986
12. Salvati P, Lamberti E, Ferrario R, Ferrario RG, Scampini G, Pugliese F, Barsotti P, Patrono C: Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis. Kidney Int 47: 1168-1175, 1995
13. 2 production in patients with systemic lupus erythematosus. J Clin Invest 76: 1011-1018, 1985
14. Pierucci A, Bianca MD, Simonetti M, Pecci G, Maurikakis G, Feriozzi S, Cinotti GA, Patrignani P, Ciabattoni G, Patrono C: Improvement of renal function with selective thromboxane antagonist in lupus nephritis. N Engl J Med 320: 273-279, 1989
15. Patrono C, Pierucci A: Renal effects of nonsteroidal anti-inflammatory drugs in chronic glomerular disease. Am J Med 81: 71-83, 1986
16. Kimberly RP, Plotz PH: Aspirin-induced depression of renal function. N Engl J Med 296: 418-424, 1977
17. Kimberly RP, Bowden RE, Keiser HR, Plotz PH: Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. Am J Med 64: 804-807, 1978
18. Smith WL, DeWitt DL: Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 15: 179-194, 1995
19. DeWitt DL, Smith WL: Primary structure of prostaglandin G/H synthase from sheep vescicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85: 1412-1416, 1988
20. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O: Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83: 483-492, 1995
21. O'Banion MK, Winn VD, Young DA: cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 89: 4888-4892, 1992
22. Wu KK: Cyclooxygenase 2 induction: Molecular mechanism and pathophysiologic roles. J Lab Clin Med 128: 242-245, 1996
23. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P: Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91: 12013-12017, 1994
24. Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR, Hla T: Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J Clin Invest 93: 1095-1101, 1994
25. Hempel SL, Monick MM, Hunninghake GW: Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest 93: 391-396, 1994
26. Arias-Negrete S, Keller K, Chadee K: Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. Biochem Biophys Res Commun 208: 582-589, 1995
27. 2 mRNA in lung fibroblasts and endothelial cells in culture. Biochem Biophys Res Commun 197: 1465-1474, 1993
28. Rzymkiewicz D, Leingang K, Baird N, Morrison AR: Regulation of prostaglandin endoperoxide synthase gene expression in rat mesangial cells by interleukin-1β. Am J Physiol 266: F39-F45, 1994
29. Linker-Israeli M: Cytokine abnormalities in human lupus. Clin Immunol Immunopathol 63: 10-12, 1992
30. Tan EM, Cohen AS, Fries J, Masi AT, Mc Shane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277, 1982
31. Appel BG, Silva FG, Pirani CL: Renal involvement in systemic lupus erythematosus (SLE): A study of 56 patients emphasizing histological classification. Medicine (Baltimore) 57: 371-410, 1978
32. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ cyclooxygenase homologue. J Biol Chem 266: 12866-12872, 1991
33. Boyum A: Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 21: 77-89, 1968
34. Perper RJ, Zee TW, Mickelson MM: Purification of lymphocytes and platelets by gradient centrifugation. J Lab Clin Med 72: 842-848, 1968
35. 2 synthesis induced by cyclosporine A. Am J Physiol 257: F77-F85, 1989
36. Rambaldi A, Young DC, Griffin JD: Expression of the M-CSF (CSF-1) gene by human monocytes. Blood 69: 1409-1413, 1987
37. Feinberg AP, Volgestein B: A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132: 6-13, 1983
38. Fort P, Marty L, Piechaczy M, el Sabrouty S, Dani C, Jeanteur P, Blanchard JM: Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res 13: 1431-1432, 1985
39. Créminon C, Frobert Y, Habib A, Maclouf J, Pradelles P, Grassi J: Immunological studies of human constitutive cyclooxygenase (COX-1) using enzyme immunometric assay. Biochim Biophys Acta 1254: 333-340, 1995
40. Kelly PMA, Bliss E, Morton JA, Burns J, McGee JO: Monoclonal antibody EBM/11: High cellular specificity for human macrophages. J Clin Pathol 41: 510-515, 1988
41. Nakstad B, Lyberg T, Baklien K, Boye NP: Antigenic specificity of human alveolar macrophages and blood monocytes studied by an immunofluorescence technique. J Pathol 157: 99-107, 1989
42. Lagarde M, Bryon PA, Guicardant M, Dechavanne M: A simple and efficient method for platelet isolation from their plasma. Thromb Res 17: 581-588, 1980
43. Godfrey K: Comparing the means of several groups. In: Medical Uses of Statistics, edited by Bailar JC III, Mosteller F, Waltham, Massachusetts Medical Society, 1986, pp 210-234
44. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA: Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 5: 2304-2312, 1991
45. Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function. Am J Physiol 272: F460-F468, 1997
46. Roberts LJ II, Sweetman BJ, Oates JA: Metabolism of thromboxane B2 production in healthy subjects. J Biol Chem 256: 8384-8393, 1981
47. Patrignani P, Filabozzi P, Patrono C: Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69: 1366-1372, 1982
48. 2 synthetase inhibitor, DP-1904. Lupus 5: 129-138, 1996
49. Rota S, Rambaldi A, Gaspari F, Noris M, Daina E, Benigni A, Perna A, Donadelli R, Remuzzi G, Garattini S: Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. Kidney Int 42: 981-990, 1992
50. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA: Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 97: 2672-2679, 1996
51. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K: Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91: 3228-3232, 1994
52. Bucala R, Ritchlin C, Winchester R, Cerami A: Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J Exp Med 173: 569-574, 1991
53. Eatgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW: Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 2: 706-709, 1988
54. Tanaka Y, Saito K, Suzuki H, Eto S, Yamashita U: Inhibitory effect of anti-class II antibody on the spontaneous activation of B cells in patients with systemic lupus erythematosus: Analysis with IL-1 production and IL-1 receptor expression. J Immunol 143: 1584-1590, 1989
55. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR: Elevated levels of endogenous IL-6 in systemic lupus erythematosus. J Immunol 147: 117-123, 1991
56. Gotti E, Casiraghi F, Noris M, Benigni A, Remuzzi G: Enhanced urinary interleukin-6 (IL-6) and interleukin-1β (IL-1β) parallel renal disease activity in systemic lupus erythematosus (SLE) [Abstract]. J Am Soc Nephrol 5: 749, 1994
57. Linker-Israeli M, Wallace DJ, Jordan SC, Klinenberg JR: Demonstration of IL-1, IL-6 and IFN-γ in SLE kidney biopsies [Abstract]. Arthritis Rheum 34(Suppl): R20, 1991
58. Spurney RF, Fan PY, Ruiz P, Sanfilippo F, Pisetsky DS, Coffman TM: Thromboxane receptor blockade reduces renal injury in murine lupus nephritis. Kidney Int 41: 973-982, 1992
59. Clark WF, Parbtani A, McDonald JWD, Taylor N, Reid BD, Kreeft J: The effects of thromboxane synthase inhibitor, a prostacyclin analog, and PGE1 on the nephritis of the NZB/W F1 mouse. Clin Nephrol 28: 288-294, 1987
60. Patrignani P, Filabozzi P, Catella F, Pugliese F, Patrono C: Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism. J Pharmacol Exp Ther 228: 472-477, 1984
61. Patrignani P, Catella F, Filabozzi P, Pugliese F, Pierucci A, Simonetti BM, Forni L, Segni M, Patrono C: Differential effects of OKY-O46, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin endoperoxide metabolism [Abstract]. Clin Res 32: 246A, 1984
62. Patrono C, Patrignani C, Catella F, Forni L, Segni M, Filabozzi P, Pugliese F, Pierucci A, Simonetti BM: Resistance of renal thromboxane synthase to inhibition by dazoxiben, OKY-046 and UK-38,485 in man [Abstract]. Presented at the 9th International Congress of Pharmacology, No. 314, London, Macmillan Press, Ltd., 1984
63. Kontessis PS, Jones SL, Barrow SE, Stratton PD, Alessandrini P, De Cosmo S, Ritter JM, Viberti GC: Effect of selective ihibition of thromboxane synthesis on renal function in diabetic nephropathy. J Lab Clin Med 121: 415-423, 1993
64. Schlondorff D: Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 44: 643-653, 1993
65. Hayllar J, Bjarnason I: NSAIDs, COX-2 inhibitors and the gut. Lancet 346: 521-522, 1995
66. Bjarnason I, Hayllar J, Parker J, Schupp A, Macpherson A: A randomised double blind crossover comparative endoscopy study on the gastroduodenal tolerability of flosulide and naproxen [Abstract]. Gastroenterology 106: A53, 1994
67. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384: 644-648, 1996